Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

In a new study, the researchers have shown that the CRISPR–Cas3 system can induce reliable, extensive deletions of the ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

In conjunction with the strategic evolution, the Company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer. Based on a revised capital allocation strategy, the Company extended its ...

Existing gene-editing technologies have led to significant advances in both medicine and food production. However, momentum appears to be slowing, particularly in health applications, as early hype is ...

Waking up this morning to news of the much-deserved Nobel Prize win for Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing" confirms the importance of ...